TRIGR Therapeutics

TRIGR Therapeutics is a privately-held biotechnology company headquartered in Irvine, California. The company is a small business with a team of three employees. TRIGR Therapeutics focuses on the development and commercialization of cutting-edge therapeutics for diseases currently lacking effective treatment options. Their primary area of expertise is in the field of cancer immunotherapy, with a particular focus on antibody-based therapies. TRIGR’s pipeline includes both clinical and pre-clinical stage programs targeting novel and established cancer-related pathways. The company collaborates with research and development organizations like ABL Bio in South Korea to advance promising immunotherapy candidates into globally approved treatments. TRIGR’s innovative approach to immunotherapy aims to overcome biological obstacles within the tumor microenvironment, ultimately leading to more effective treatment outcomes for cancer patients. The company’s immunotherapies are designed to enhance the body’s natural immune response, empowering patients in the fight against cancer. To learn more about TRIGR Therapeutics and their groundbreaking work in cancer immunotherapy, visit their website at trigrrx.com.